KIA
VRTX icon

KCM Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

KCM Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$542K Buy
1,213
+237
+24% +$111K 0.02% 259
2025
Q4 		$442K Buy
+976
New +$421K 0.01% 285
2014
Q4 		– Sell
-2,789
Closed -$313K – 534
2014
Q3 		$313K Buy
+2,789
New +$266K 0.03% 400

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

KCM Investment Advisors's VRTX Position: Q1 2026 in Review

KCM Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q1 2026, buying an estimated $111K and bringing the position to 1,213 shares worth $542K. The position accounts for 0.02% of the portfolio, ranked #259.

KCM Investment Advisors first reported a position in VRTX in Q3 2014 and has held it in 3 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • KCM Investment Advisors held 1,213 shares of Vertex Pharmaceuticals worth $542K as of Q1 2026.
  • KCM Investment Advisors bought 237 Vertex Pharmaceuticals shares in Q1 2026, an estimated $111K.
  • Vertex Pharmaceuticals made up 0.02% of KCM Investment Advisors's portfolio in Q1 2026, its #259 holding.
  • KCM Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 3 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on KCM Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.